Branded generics are generic drugs that have been given a proprietary market name. They may be marketed in a similar way as branded drugs. Branded generic drugs attach proprietary names to generic drug molecules. Some branded generics are specially made as novel dosage forms of off-patent drugs, filling in a dosage gap while offering consumers a name that is likely easier to remember than the true generic name. Branded generics are a small but profitable segment of the pharmaceutical market. Branded generics go through the same FDA approval process as other generics after branded drug patents expire.

According to a report released by VOXEU, with healthcare budgets worldwide under pressure, switching to branded generics seems a natural cost saver. Branded generics are cheaper alternatives to branded medicines, offering efficiency gains to any healthcare system. For instance, in 2016, US$ 253 billion was generated by generic medicines accounting for one-quarter of a trillion dollars. Additionally, US$ 1.6 trillion in healthcare savings in the same year accounted for in the US healthcare system evaluating a 10-year saving due to the availability of low-cost generics.

Top Companies Analysis-

GlaxoSmithKline plc
Bausch Health (Valeant Pharmaceuticals)
Sandoz International Gmbh
Aspen Holdings
Par Pharmaceuticals
Lupin
Sanofi
AstraZeneca
Dr. Reddy's Laboratories Inc.
Hetero

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global Industry based on various segments. It also provides Industry size and forecast estimates from the year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Industry by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyses these key players in the global Branded Generics Industry. These players have incorporated various strategies such as expansion, new product launches, partnerships, and others to increase their Industry penetration and strengthen their position in the industry. The report is helpful in assessing the operating segments, their business performance & product portfolio, and so on.

The Branded Generics Market report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country, and sub-region during the estimated period. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Branded Generics market in these regions.

Segments-

Distribution Channel-Based Insights
Based on distribution channel, the branded generics market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies segment is likely to hold the largest share of the market in 2022. Moreover, the online pharmacies segment is anticipated to register the highest CAGR in the market during the forecast period.

Drug Class-Based Insights
Based on drug class, the branded generics market is categorized into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. The others segment is likely to hold the largest share of the market in 2022. However, the hormones segment is anticipated to register the highest CAGR in the market during the forecast period.

Formulation Type-Based Insights
Based on formulation type, the branded generics market is segmented into oral, parenteral, topical, and others. In 2022, the oral segment held the largest share of the market by formulation type. However, the parenteral segment is expected to grow at the fastest CAGR from 2022 to 2028.

About Us:                    

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, and Chemicals

Contact Us:                        

If you have any queries about this report or if you would like further information, please

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876